TN2009000444A1 - Combination therapy with a compound acting as a plateletadp receptor inhibitor - Google Patents

Combination therapy with a compound acting as a plateletadp receptor inhibitor

Info

Publication number: TN2009000444A1
Authority: TN; Tunisia
Prior art keywords: plateletadp; combination therapy; receptor inhibitor; compound acting; acting
Prior art date: 2007-05-02

Application number

TNP2009000444A

Other languages

English (en)

Inventor

Pamela B Conley

Patrick Andre

Uma Sinha

Original Assignee

Portola Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-02

Filing date

2009-10-23

Publication date

2011-03-31

2009-10-23 Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc

2011-03-31 Publication of TN2009000444A1 publication Critical patent/TN2009000444A1/fr

Links

238000002648 combination therapy Methods 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
108091006082 receptor inhibitors Proteins 0.000 title 1
WUPZRLYEGIXBNO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea Chemical compound O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 WUPZRLYEGIXBNO-UHFFFAOYSA-N 0.000 abstract 1
208000007536 Thrombosis Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

TNP2009000444A 2007-05-02 2009-10-23 Combination therapy with a compound acting as a plateletadp receptor inhibitor TN2009000444A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US91564907P	2007-05-02	2007-05-02
US91591107P	2007-05-03	2007-05-03
US94792107P	2007-07-03	2007-07-03
US97870007P	2007-10-09	2007-10-09
PCT/US2008/062561 WO2008137787A2 (fr)	2007-05-02	2008-05-02	Thérapie de combinaison avec un composé agissant comme inhibiteur de récepteur à l'adp de plaquettes

Publications (1)

Publication Number	Publication Date
TN2009000444A1 true TN2009000444A1 (en)	2011-03-31

Family

ID=39587017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000444A TN2009000444A1 (en)	2007-05-02	2009-10-23	Combination therapy with a compound acting as a plateletadp receptor inhibitor

Country Status (21)

Country	Link
US (2)	US20080279845A1 (fr)
EP (2)	EP2586439A1 (fr)
JP (1)	JP5439363B2 (fr)
KR (1)	KR101509829B1 (fr)
CN (1)	CN101686959B (fr)
AU (1)	AU2008247435A1 (fr)
BR (1)	BRPI0811000A2 (fr)
CA (1)	CA2684722A1 (fr)
CO (1)	CO6241105A2 (fr)
EA (1)	EA020045B1 (fr)
EC (1)	ECSP099775A (fr)
ES (1)	ES2467468T3 (fr)
GT (1)	GT200900283A (fr)
HK (1)	HK1138765A1 (fr)
IL (1)	IL201826A (fr)
MA (1)	MA31396B1 (fr)
MX (1)	MX2009011755A (fr)
NZ (2)	NZ599556A (fr)
PT (1)	PT2146705E (fr)
TN (1)	TN2009000444A1 (fr)
WO (1)	WO2008137787A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001250783A1 (en)	2000-02-29	2001-09-12	Cor Therapeutics, Inc.	Benzamides and related inhibitors of factor xa
WO2006002099A2 (fr) *	2004-06-18	2006-01-05	Millennium Pharmaceuticals, Inc.	Inhibiteurs du facteurs xa
US7696352B2 (en) *	2004-06-18	2010-04-13	Millennium Pharmaceuticals, Inc.	Factor Xa inhibitors
SI2404919T1 (sl)	2005-11-08	2013-12-31	Vertex Pharmaceuticals Incorporated	Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
US20090186810A1 (en) *	2006-03-27	2009-07-23	Portola Pharmaceuticals, Inc.	Potassium channel modulators and platelet procoagulant activity
CN101490036B (zh) *	2006-05-05	2013-07-17	米伦纽姆医药公司	Xa因子抑制剂
PT2404906E (pt) *	2006-11-02	2015-11-02	Millennium Pharm Inc	Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
CA2674924A1 (fr) *	2007-01-05	2008-07-17	Millennium Pharmaceuticals, Inc.	Inhibiteurs du facteur xa
KR101473207B1 (ko) *	2007-04-13	2014-12-16	밀레니엄 파머슈티컬스 인코퍼레이티드	Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
PL3170818T3 (pl)	2007-12-07	2020-09-21	Vertex Pharmaceuticals Incorporated	Stałe formy kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
AR074347A1 (es) *	2008-11-14	2011-01-12	Portola Pharm Inc	Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso
US8742120B2 (en)	2009-12-17	2014-06-03	Millennium Pharmaceuticals, Inc.	Methods of preparing factor xa inhibitors and salts thereof
EP2513094B1 (fr) *	2009-12-17	2015-12-16	Millennium Pharmaceuticals, Inc.	Sels et formes cristallines d'inhibiteur de facteur xa
ES2548845T3 (es) *	2009-12-23	2015-10-21	Ratiopharm Gmbh	Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
CA2792993A1 (fr) *	2010-01-21	2011-07-28	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Composition particuliere pour son application comme medicament
SMT202000034T1 (it) *	2010-02-25	2020-03-13	Pfizer	Formulazioni di apixaban
WO2011127241A2 (fr)	2010-04-07	2011-10-13	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration
TW201221128A (en) *	2010-09-01	2012-06-01	Portola Pharm Inc	Crystalline forms of a factor Xa inhibitor
AU2012234325B2 (en) *	2011-03-29	2016-08-11	Sanofi	Benzoic acid salt of Otamixaban
WO2013033370A1 (fr) *	2011-08-31	2013-03-07	Portola Pharmaceuticals, Inc.	Prévention et traitement de la thrombose chez des patients médicalement malades
US9708308B2 (en)	2012-12-19	2017-07-18	Merck Sharp Dohme Corp.	Factor IXa inhibitors
US9695198B2 (en)	2012-12-19	2017-07-04	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
WO2014099695A1 (fr) *	2012-12-19	2014-06-26	Merck Sharp & Dohme Corp.	Inhibiteurs du facteur ixa
US9200268B2 (en)	2012-12-27	2015-12-01	Portola Pharmaceuticals, Inc.	Compounds and methods for purification of serine proteases
NZ720958A (en)	2013-11-12	2022-02-25	Vertex Pharma	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
US9676723B2 (en) *	2014-02-11	2017-06-13	Merck Sharp & Dohme Corp	Factor XIa inhibitors
CN106831553A (zh) *	2015-09-11	2017-06-13	天津科伦药物研究有限公司	贝曲西班或其类似物的制备方法
CN105250286A (zh) *	2015-11-13	2016-01-20	谭惠娟	一种抗血栓组合物
EP3254674A1 (fr) *	2016-06-08	2017-12-13	Sandoz Ag	Compositions pharmaceutiques de betrixaban maléate
US10875851B2 (en)	2016-11-18	2020-12-29	Merck Sharp & Dohme Corp.	Factor XIIa inhibitors
US11654036B2 (en)	2020-05-26	2023-05-23	Elixir Medical Corporation	Anticoagulant compounds and methods and devices for their use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440147B1 (en) *	1998-09-03	2002-08-27	Rubicor Medical, Inc.	Excisional biopsy devices and methods
US6509348B1 (en) *	1998-11-03	2003-01-21	Bristol-Myers Squibb Company	Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6297233B1 (en)	1999-02-09	2001-10-02	Bristol-Myers Squibb Company	Lactam inhibitors of FXa and method
US6844367B1 (en) *	1999-09-17	2005-01-18	Millennium Pharmaceuticals, Inc.	Benzamides and related inhibitors of factor Xa
EP1216228B1 (fr)	1999-09-17	2008-10-29	Millennium Pharmaceuticals, Inc.	BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
US6906063B2 (en) *	2000-02-04	2005-06-14	Portola Pharmaceuticals, Inc.	Platelet ADP receptor inhibitors
AU2001250783A1 (en)	2000-02-29	2001-09-12	Cor Therapeutics, Inc.	Benzamides and related inhibitors of factor xa
US20040192753A1 (en)	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US7235567B2 (en)	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP1330544A4 (fr)	2000-09-26	2005-04-06	Univ Duke	Aptameres d'arn et procede d'identification desdits aptameres
US7312235B2 (en) *	2001-03-30	2007-12-25	Millennium Pharmaceuticals, Inc.	Benzamide inhibitors of factor Xa
CN1780823A (zh) *	2003-04-09	2006-05-31	日本烟草产业株式会社	杂芳族五环化合物及其医药应用
WO2005035520A1 (fr)	2003-10-03	2005-04-21	Portola Pharmaceuticals, Inc.	Isoquinoleinones substituees
CN1886398A (zh) *	2003-10-09	2006-12-27	米伦纽姆医药公司	作为Xa因子抑制剂的经硫醚取代的苯甲酰胺
US7696352B2 (en) *	2004-06-18	2010-04-13	Millennium Pharmaceuticals, Inc.	Factor Xa inhibitors
WO2006002099A2 (fr) *	2004-06-18	2006-01-05	Millennium Pharmaceuticals, Inc.	Inhibiteurs du facteurs xa
US20090075949A1 (en) *	2004-10-25	2009-03-19	Wolfgang Eisert	Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
CA2596444A1 (fr)	2005-02-02	2006-08-10	Vitae Pharmaceuticals, Inc.	1-acylamino-2-hydroxy-3-amino-w-arylalkanes comme inhibiteurs de la renine
US7467697B2 (en) *	2005-10-07	2008-12-23	Ford Global Technologies, Llc	Electromagnetic coupling device for engine accessories
EP2428514A1 (fr) *	2005-11-03	2012-03-14	Portola Pharmaceuticals, Inc.	[4-(6-halo-7-substitution-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-péenyl]-5-chloro-thiophène-2-yl-sulfonylurées et formes et procédés correspondants
CA2627086C (fr) *	2005-11-08	2016-04-05	Millennium Pharmaceuticals, Inc.	Nouveaux sels pharmaceutiques et polymorphes d'un inhibiteur du facteur xa
US20090186810A1 (en)	2006-03-27	2009-07-23	Portola Pharmaceuticals, Inc.	Potassium channel modulators and platelet procoagulant activity
CN101490036B (zh)	2006-05-05	2013-07-17	米伦纽姆医药公司	Xa因子抑制剂
PT2101760E (pt) *	2006-12-08	2013-05-07	Millennium Pharm Inc	Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
CA2674924A1 (fr) *	2007-01-05	2008-07-17	Millennium Pharmaceuticals, Inc.	Inhibiteurs du facteur xa
KR101473207B1 (ko) *	2007-04-13	2014-12-16	밀레니엄 파머슈티컬스 인코퍼레이티드	Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법

2008
- 2008-05-02 PT PT87475901T patent/PT2146705E/pt unknown
- 2008-05-02 EP EP13151486.1A patent/EP2586439A1/fr not_active Withdrawn
- 2008-05-02 BR BRPI0811000-0A2A patent/BRPI0811000A2/pt not_active Application Discontinuation
- 2008-05-02 NZ NZ599556A patent/NZ599556A/xx not_active IP Right Cessation
- 2008-05-02 CN CN200880021658.3A patent/CN101686959B/zh not_active Expired - Fee Related
- 2008-05-02 EA EA200901442A patent/EA020045B1/ru not_active IP Right Cessation
- 2008-05-02 US US12/114,706 patent/US20080279845A1/en not_active Abandoned
- 2008-05-02 JP JP2010506696A patent/JP5439363B2/ja not_active Expired - Fee Related
- 2008-05-02 AU AU2008247435A patent/AU2008247435A1/en not_active Abandoned
- 2008-05-02 CA CA002684722A patent/CA2684722A1/fr not_active Abandoned
- 2008-05-02 WO PCT/US2008/062561 patent/WO2008137787A2/fr active Application Filing
- 2008-05-02 KR KR1020097024870A patent/KR101509829B1/ko not_active Expired - Fee Related
- 2008-05-02 EP EP08747590.1A patent/EP2146705B1/fr not_active Not-in-force
- 2008-05-02 NZ NZ581324A patent/NZ581324A/en not_active IP Right Cessation
- 2008-05-02 ES ES08747590.1T patent/ES2467468T3/es active Active
- 2008-05-02 MX MX2009011755A patent/MX2009011755A/es active IP Right Grant
2009
- 2009-10-23 TN TNP2009000444A patent/TN2009000444A1/fr unknown
- 2009-10-29 IL IL201826A patent/IL201826A/en not_active IP Right Cessation
- 2009-10-30 GT GT200900283A patent/GT200900283A/es unknown
- 2009-11-20 CO CO09132196A patent/CO6241105A2/es not_active Application Discontinuation
- 2009-11-26 MA MA32375A patent/MA31396B1/fr unknown
- 2009-12-01 EC EC2009009775A patent/ECSP099775A/es unknown
2010
- 2010-06-01 HK HK10105391.2A patent/HK1138765A1/xx not_active IP Right Cessation
- 2010-10-20 US US12/908,837 patent/US8946219B2/en active Active

Also Published As

Publication number	Publication date
MA31396B1 (fr)	2010-05-03
MX2009011755A (es)	2010-02-12
US20080279845A1 (en)	2008-11-13
NZ599556A (en)	2013-10-25
EP2146705B1 (fr)	2014-03-05
CN101686959B (zh)	2014-05-07
US8946219B2 (en)	2015-02-03
AU2008247435A1 (en)	2008-11-13
EA200901442A1 (ru)	2010-06-30
NZ581324A (en)	2012-05-25
KR101509829B1 (ko)	2015-04-06
CO6241105A2 (es)	2011-01-20
CN101686959A (zh)	2010-03-31
KR20100023836A (ko)	2010-03-04
EA020045B1 (ru)	2014-08-29
HK1138765A1 (en)	2010-09-03
WO2008137787A3 (fr)	2009-02-05
PT2146705E (pt)	2014-05-23
EP2146705A2 (fr)	2010-01-27
GT200900283A (es)	2011-10-05
IL201826A0 (en)	2010-06-16
ECSP099775A (es)	2010-01-29
IL201826A (en)	2014-08-31
EP2586439A1 (fr)	2013-05-01
ES2467468T3 (es)	2014-06-12
WO2008137787A2 (fr)	2008-11-13
US20110033459A1 (en)	2011-02-10
JP5439363B2 (ja)	2014-03-12
BRPI0811000A2 (pt)	2015-01-27
JP2010526103A (ja)	2010-07-29
CA2684722A1 (fr)	2008-11-13

Publication	Publication Date	Title
TN2009000444A1 (en)	2011-03-31	Combination therapy with a compound acting as a plateletadp receptor inhibitor
WO2013003629A3 (fr)	2013-04-11	Procédés et compositions visant à inhiber la résorption osseuse
TN2014000128A1 (en)	2015-07-01	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
TNSN08283A1 (en)	2009-10-30	Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
SG179418A1 (en)	2012-04-27	Inhibitors of the hedgehog pathway
JO2885B1 (en)	2015-03-15	Protein kinase inhibitors
MY146111A (en)	2012-06-29	Acylaminopyrazoles as fgfr inhibitors
MX2011009796A (es)	2011-12-14	Inhibidores de la cinasa pi3.
PT1940839E (pt)	2013-10-10	Inibidores de piridopirimidinona pi3k alfa
TN2012000062A1 (en)	2013-09-19	Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
PH12013501594A1 (en)	2014-05-12	Substituted indazole derivatives active as kinase inhibitors
IL182218A0 (en)	2007-09-20	Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
GEP20084551B (en)	2008-11-25	4-phenylamino-quinazolin-6-yl-amides
MX2007013624A (es)	2008-02-12	Inhibidores de proteina cinasa.
MX2009009238A (es)	2009-09-08	Nuevos inhibidores de fosfodiesterasa.
WO2009025785A3 (fr)	2009-09-11	Ligands de récepteur cb2 pour le traitement de la douleur
MY154591A (en)	2015-06-30	Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
MX2009011059A (es)	2009-11-26	Aminopirimidinas utiles como inhibidores de cinasas.
IN2012DN02502A (fr)	2015-08-28
MX2010003269A (es)	2010-08-02	Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
IL194057A0 (en)	2009-08-03	Pyrimidine, quinazoline, pteridine and triazine derivatives
PL1853232T3 (pl)	2010-01-29	Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
IL195016A0 (en)	2009-08-03	1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200626158A (en)	2006-08-01	Naphthaline derivatives
TNSN08385A1 (en)	2009-12-29	Delayed-release glucocorticoid treatment of rheumatoid disease